Sabena Sultan
Director Técnico/Científico/I+D en Cell Therapy Ltd. .
Perfil
Sabena Sultan is currently the Director & Global Head-Research at Cell Therapy Ltd.
Prior to this, he worked as a Principal Investigator at University College London and King's College London.
He holds a doctorate degree from Imperial College London.
Cargos activos de Sabena Sultan
Empresas | Cargo | Inicio |
---|---|---|
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Director Técnico/Científico/I+D | - |
Antiguos cargos conocidos de Sabena Sultan.
Empresas | Cargo | Fin |
---|---|---|
University College London | Corporate Officer/Principal | - |
King's College London | Corporate Officer/Principal | - |
Formación de Sabena Sultan.
Imperial College London | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Sabena Sultan